CION Ameerpet
Pancreatic Cancer · Prognosis, Survival & Recurrence · Reviewed by CION Oncologists
Pancreatic cancer survival by stage — how to read the numbers honestly
A survival figure describes a group of people diagnosed years ago. It is not a forecast for you. This page explains what each stage figure really measures, why resectability matters more than the stage number, and what genuinely shifts the outlook.
- A survival rate describes a group — it was never built to predict one person's course.
- Resectability outranks the stage number — whether the tumour can be removed shapes the plan.
- Published figures lag real care — they count people treated years before the number appeared.
- Neuroendocrine tumours are a separate story — their outlook is better, and adenocarcinoma figures do not apply.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What a Survival Figure Actually Measures
Almost everyone searches for a pancreatic cancer survival rate within a day or two of the diagnosis. It is the most natural thing in the world to look for, and it is also the number most often misread. A survival rate is a description of a large group of people diagnosed some years ago. It is not a prediction about you, and it was never designed to be one.
Two different things are usually being confused. The first is the stage — the TNM description of how large the tumour is, whether lymph nodes are involved, and whether it has reached distant organs. The second is resectability — whether the tumour can actually be removed by an operation. These answer different questions, and it is the second that drives most of what happens next. Pancreatic cancer staging (TNM) set against resectability puts the two systems side by side.
There are four specific reasons a published pancreatic cancer survival rate tends to mislead the person reading it. It is historical: the people counted in it were treated with what was available years before the figure appeared. It is averaged: a tumour that was removed and a tumour that had already spread widely sit inside the same headline number. It mixes tumour types: slow-growing neuroendocrine tumours are sometimes pooled with ductal adenocarcinoma, which behaves very differently. And it describes a group, not a person — your general health, your nutrition, whether an operation is possible and how the tumour answers treatment all sit outside the average.
None of that makes the figures useless. It makes them the starting point for a specific conversation rather than an answer on their own. The rest of this page explains what each stage really describes, what genuinely shifts the outlook, and the questions worth asking so that the number you are given is actually about your situation. For the wider picture first, the complete pancreatic cancer guide covers diagnosis, treatment and support.
Did you know? The NCCN Guidelines for pancreatic adenocarcinoma sort every newly diagnosed tumour into one of four resectability categories — resectable, borderline resectable, locally advanced and metastatic — defined by exactly how far the tumour touches or surrounds the major vessels behind the pancreas, including the superior mesenteric artery, the coeliac axis, the common hepatic artery, and the superior mesenteric and portal veins. That category, rather than the stage number by itself, is what decides whether an operation is on the table now, later, or not at all. It is also the single most useful thing to know before you read any survival figure, because published figures average all four categories together into one line.
Stage by stage
What Each Stage Actually Describes
Read this as a map of what the label means and where the operation question sits — not as a way to reach your own forecast. The last column is the part most pages leave out.
| Stage | What it describes | Where the operation question sits | Why the headline figure misleads here |
|---|---|---|---|
| Stage I | Tumour confined to the pancreas, with no lymph node involvement and no distant spread. | Usually removable at presentation, with chemotherapy afterwards. The outlook after successful pancreatic cancer surgery covers this group specifically. | Pooled figures include people who were fit enough for an operation and people who were not, which are very different situations. |
| Stage II | Larger, or with nearby lymph nodes involved, but still no distant spread. | Often removable. Some tumours here are borderline and are given systemic treatment first, to try to shrink them into the operable group. | People move between groups after diagnosis when treatment downstages a tumour. No single stage figure captures that movement. |
| Stage III | The tumour involves the major vessels behind the pancreas. Often called locally advanced. | Not removable at presentation. Systemic treatment, sometimes with radiation, comes first and the vessels are then reassessed. | Some people in this group later become operable. The headline number counts them alongside those who never do. |
| Stage IV | Spread to distant organs, most often the liver or the lining of the abdomen. Where and how pancreatic cancer spreads explains the routes. | Treatment is systemic, aimed at control, symptom relief and quality of life. Living with advanced pancreatic cancer covers what that looks like. | This stage runs from a single small deposit — see oligometastatic pancreatic cancer — to widespread disease, all inside one figure. |
Pancreatic neuroendocrine tumours are staged on their own system and reported separately, and they carry a considerably better outlook than ductal adenocarcinoma. If your pathology report says neuroendocrine tumour, adenocarcinoma figures do not describe your situation at all — check the wording on the report itself rather than how the diagnosis was summarised in conversation.
Beyond the label
What Actually Moves the Outlook
Each of these carries more weight in a real conversation than the stage number on its own.
Resectability
Whether the tumour can be removed
The single biggest determinant. A complete operation with clear margins changes the conversation more than any other factor, which is why the category is asked for first.
Tumour type
Adenocarcinoma or neuroendocrine
Neuroendocrine tumours often grow slowly and carry a much better outlook. Confirming the type on biopsy is the first thing that should happen, before any figure is read.
Biology
Grade, node status and the CA 19-9 trend
How the tumour looks under the microscope, whether nodes were involved, and whether CA 19-9 falls with treatment all say more than the stage label alone.
Fitness
Performance status and nutrition
Being well enough to complete a full course of systemic treatment matters enormously. Enzyme replacement and nutrition support are part of treatment, not an optional extra.
Response
How the tumour answers treatment
A tumour that shrinks on the first scan after treatment starts is telling you something the stage at diagnosis could not. So is one that does not.
Everything together
The full prognostic picture
No single factor decides the outlook on its own. What affects pancreatic cancer prognosis takes each of these apart in detail.
Take this to your appointment
Questions That Make the Number About You
Written down, in the order they are most useful. None of them is a difficult question to ask.
- Is my tumour resectable, borderline, locally advanced or metastatic? Ask for the category, not only the stage number. It is the answer that shapes everything else.
- Is this ductal adenocarcinoma or a neuroendocrine tumour? The two have different outlooks and different treatment, and published figures rarely separate them clearly.
- If treatment works, could an operation become possible? Downstaging is real. It is worth asking explicitly rather than assuming the first answer is the final one.
- What would you expect over the coming months, and what would change it? A time frame given with its conditions is far more useful than a bare figure. How pancreatic cancer life expectancy figures are built explains why.
- Is this treatable, and what does treatable mean here? Treatable and curable are not the same word, and neither means untreatable. Is pancreatic cancer terminal? answers that plainly.
- How will you know if it comes back? Ask about the follow-up schedule at the start, not at the end. Pancreatic cancer recurrence — signs and monitoring sets out what is watched for.
If you have a stage written on a report and no idea what it means for you, bring the report in. We will read it with you and say plainly what it does and does not tell us. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Statistic Describes a Group. You Are Not a Group.
Your scan and pathology reports answer more of the survival question than anything you will read online.
What actually happens
How We Give You a Realistic Answer
-
Confirm what the tumour actually is
The pathology report decides whether adenocarcinoma figures apply to you at all. Tissue is usually obtained by endoscopic ultrasound with a fine-needle sample.
Biopsy coordinated with specialist endoscopy partners -
Establish the resectability category
A pancreatic-protocol contrast CT is read specifically for the tumour's relationship to the arteries and veins behind the pancreas. This is the finding that matters most.
Ordered and reported in-house at CION -
Baseline the markers
CA 19-9 and routine bloods are taken at the outset, so that the trend over time — which is far more informative than any single reading — can be followed properly.
In-house at CION -
Review the case as a team
Scans, pathology and general health are discussed together rather than by one doctor alone, so the plan reflects what medical oncology, radiation oncology and the surgical partners each think is achievable.
Tumour board at CION -
Set the plan, and write down what would change it
Chemotherapy, chemoradiation or SBRT is planned around the category, with the reassessment points agreed in advance. Pancreatic cancer treatment in Hyderabad sets out the options in full.
Systemic therapy and radiation in-house at CION -
Answer the survival question honestly
We tell you what the published figures describe, which parts of them apply to you and which do not. We will not invent a number, and we will not pretend a group average is a forecast.
Free 45-minute consultation
Plainly stated
What CION Delivers, and What Is Coordinated
Being clear about this early saves a difficult conversation later. Your first consultation is free and lasts 45 minutes, and it is a genuine review of your reports rather than a booking appointment.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient; and systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods; genetic counselling; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.
Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, including the Whipple procedure and distal pancreatectomy; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.
Both things are true
The Parts of This That Are Genuinely Hopeful
This is a serious cancer and it is often found late. Saying otherwise would be dishonest, and you would spot it. But there are specific, real reasons the picture is less fixed than the headline figures suggest.
Cure is possible when the tumour is found early and can be removed completely, usually followed by chemotherapy. Systemic treatment given first can shrink a borderline tumour enough to make an operation possible that was not possible at diagnosis. Neuroendocrine tumours carry a considerably better outlook and are treated on an entirely different track. And systemic therapy has moved on — whether pancreatic cancer survival is improving looks honestly at what has changed and what has not.
Follow-up after treatment deserves the same attention as the treatment itself. Knowing what is being watched for, and how often, makes the years afterwards far less anxious than watching for symptoms with no framework — recurrence after a Whipple procedure sets out the schedule and the signs that matter.
Bring your scan report and your pathology report to the first appointment. Those two documents answer more of the survival question than anything you will read online. Book a free consultation or call 1800 202 8726.
Take the next step
Ask for the Category, Not Only the Number
We walk this journey with you, with the time to explain what your reports actually say.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Pancreatic cancer survival by stage — your questions answered
Why does the survival rate I found online not match what my doctor told me?
Because the two are answering different questions. A published survival rate describes a large group of people diagnosed some years ago, pooled together regardless of whether their tumour could be removed, how well they were at diagnosis, or which type of pancreatic cancer they had. Your doctor is describing you: your scan, your pathology report, your general health and what is realistically possible in your case. The published figure is a historical average, and it is usually the more pessimistic of the two, because it includes people treated before current systemic therapy existed and people who were never well enough for the treatments now being offered to you. Neither number is a lie. Only one of them is about your situation, and it is the one being said out loud in the room.
What does a five-year survival rate actually measure?
It measures the proportion of people in a defined group who were still alive five years after their diagnosis was recorded. It says nothing about how they were treated, which stage they were at, whether they had an operation, or how they were living during those years. It also cannot describe anyone diagnosed recently, because five years have to pass before the data exists at all. That lag is why published figures always describe an older era of treatment than the one you are being offered now. Read it as a rough historical benchmark for a whole population, not as a countdown for one person. In pancreatic cancer specifically, the overall figure is pulled down heavily by the large share of cases found only after the tumour has already spread, which is a very different situation from a tumour found while it can still be removed.
Does the stage number or the resectability category matter more?
For decisions, resectability matters more. The stage describes what was found: tumour size, lymph node involvement and whether there is distant spread. The resectability category describes what can be done: whether the tumour can be removed now, might become removable after treatment, cannot be removed but has not spread, or has already spread to distant organs. NCCN guidance defines those categories by exactly how far the tumour contacts the major arteries and veins behind the pancreas. Two people can share a stage and still sit in different categories, and their treatment plans will look nothing alike. So when you are given a stage, ask for the category as well. That is the answer telling you whether an operation is being planned, being worked towards, or is not part of the plan.
Why are neuroendocrine tumours reported separately from other pancreatic cancers?
Because they behave differently enough that mixing them into one figure would mislead everybody. Most pancreatic cancer is ductal adenocarcinoma, which arises in the ducts and tends to grow quickly. Pancreatic neuroendocrine tumours arise in hormone-producing cells, often grow slowly, are staged on their own system, and carry a considerably better outlook. They are also treated on a different track, with different systemic options. If your pathology report says neuroendocrine tumour, adenocarcinoma survival figures simply do not describe your situation, and reading them will frighten you for no reason at all. Check the exact wording on the report itself rather than relying on how the diagnosis was summarised in conversation, and ask your oncologist to confirm which of the two you have before you read anything further.
Are published pancreatic cancer survival figures out of date?
In a specific and unavoidable sense, yes. Any survival figure needs years of follow-up before it can be calculated, so by the time it is published it describes people diagnosed and treated well before that date. Systemic therapy, radiation technique, surgical selection, nutritional support and supportive care have all moved during that gap. This does not mean the figures should be ignored, and it certainly does not mean the disease has been solved. It means the number describes a starting point that sits behind where care currently stands. Where you can, look at when the data was collected rather than when the page was written, and ask your treating team what has changed since. That is a fair question, and a good oncologist will answer it directly rather than deflecting.
Should I ask for a number at all, or is it better not to know?
Both choices are reasonable and neither is wrong. Some people need a time frame to make decisions about work, money, travel or family, and find the uncertainty harder to carry than the answer. Others find a number becomes something they count against every day, and would rather focus on the next scan and the next decision. You can also ask for it in stages: what is realistic over the coming months, what would change that, and when we would know more. You are allowed to change your mind in either direction, and you are allowed to want a different amount of detail from the rest of your family. Say plainly at the start of the conversation which you prefer, and it will be shaped around that rather than delivered the same way to everyone.
What does CION do about this, and what happens at the first visit?
The first consultation is free and lasts 45 minutes. Bring your scan report, your pathology report and any blood results. We read them with you, say which resectability category your tumour falls into and which type of pancreatic cancer it is, and explain what the published figures do and do not tell us about your case. Chemotherapy, radiation, chemoradiation and SBRT, imaging and marker follow-up, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered in-house across our 35+ centres. Pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there. We tell you before anything is booked which of these applies and where it happens.
Medical disclaimer: This page explains how pancreatic cancer survival figures are constructed and what each stage describes, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information and deliberately states no survival figure, because no published figure describes an individual; your own outlook depends on your resectability category, tumour type and general health, and should be discussed with your treating team. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.